The double blocking of the TIGIT and PD-1/PD-L1 pathway showed synergistic antitumor effects in colorectal cancer and ovary cancer by upregulating the effector activity of T cells and NK cells [23]. The gene discussed is TIGIT; the disease is ovarian cancer.